Women with acute intermittent porphyria have a defect in 5α-steroid production during the menstrual cycle

Acta Obstetricia et Gynecologica Scandinavica

Volumn 91, Issue 12, 2012, Pages 1445-1452

  Innala, Eva ^a   BÄckström, Torbjörn ^a   Poromaa, Inger Sundström ^b   Andersson, Christer ^a   Bixo, Marie ^c  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acute intermittent porphyria; allopregnanolone; menstrual cycle; pregnanolone; progesterone

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 5 AMINOLEVULINATE SYNTHASE; ELTANOLONE; ESTRADIOL; PORPHOBILINOGEN DEAMINASE; PROGESTERONE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5BETA REDUCTASE;

ACUTE INTERMITTENT PORPHYRIA; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLUMN CHROMATOGRAPHY; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS LUTEUM; DISEASE ACTIVITY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; GENE MUTATION; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; OUTCOME ASSESSMENT; OVULATION; PREVALENCE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RADIOIMMUNOASSAY; STEROID METABOLISM; STEROID RELEASE; SWEDEN;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ADULT; CASE-CONTROL STUDIES; ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; PORPHYRIA, ACUTE INTERMITTENT; PREGNANOLONE; PROGESTERONE; STATISTICS, NONPARAMETRIC; SWEDEN;

EID: 84870930981     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2012.01536.x     Document Type: Article

References (40)

1. Thunell S, Floderus Y, Henrichson A, Harper P,. Porphyria in Sweden. Physiol Res. 2006; 55: S109-18.
2. OMIM Online Mendelian Inheritance in Man 2010. Available online at: http://www.ncbi.nlm.nih.gov/Omim/getmap.cgi?l176000 (accessed June, 2010).
3. Andersson C, Floderus Y, Wikberg A, Lithner F,. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study. Scand J Clin Lab Invest. 2000; 60: 643-8.
4. Anderson KE, Sassa S, Bishop DF, Desnick RJ,. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In:, Scriver JRBA, Sly WS, Valle D, (eds). The metabolic and molecular bases of inherited disease, 8th edn. chapter 124, New York: McGraw-Hill, 2001 pp. 3008-20.
5. Bylesjö I, Wikberg A, Andersson C,. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest. 2009; 69: 612-8.
6. Granick S,. The induction in vitro of the synthesis of δ-aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones, and foreign chemicals. J Biol Chem. 1966; 241: 1359-75.
7. Kauppinen R, Mustajoki P,. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore). 1992; 71: 1-13.
8. Hultdin J, Schmauch A, Wikberg A, Dahlquist G, Andersson C,. Acute intermittent porphyria in childhood: a population-based study. Acta Paediatr. 2003; 92: 562-8.
9. Levit EJ, Nodine JH, Perloff WH,. Progesterone-induced porphyria; case report. Am J Med. 1957; 22: 831-3.
10. Zimmerman TS, McMillin JM, Watson CJ,. Onset of manifestations of hepatic porphyria in relation to the influence of female sex hormones. Arch Intern Med. 1966; 118: 229-40.
11. Stein JA, Tschudy DP,. Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine (Baltimore). 1970; 49: 1-16.
12. McColl KE, Wallace AM, Moore MR, Thompson GG, Goldberg A,. Alterations in haem biosynthesis during the human menstrual cycle: studies in normal subjects and patients with latent and active acute intermittent porphyria. Clin Sci (Lond). 1982; 62: 183-91.
13. Anderson KE, Spitz IM, Sassa S, Bardin CW, Kappas A,. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med. 1984; 311: 643-5.
14. Andersson C, Innala E, Backstrom T,. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med. 2003; 254: 176-83.
15. Kappas A, Granick S,. Steroid induction of porphyrin synthesis in liver cell culture. II. The effects of heme, uridine diphosphate glucuronic acid, and inhibitors of nucleic acid and protein synthesis on the induction process. J Biol Chem. 1968; 243: 346-51.
16. Sassa S, Bradlow HL, Kappas A,. Steroid induction of δ- aminolevulinic acid synthase and porphyrins in liver. Structure-activity studies and the permissive effects of hormones on the induction process. J Biol Chem. 1979; 254: 10011-20.
17. Kappas A, Bradlow HL, Gillette PN, Levere RD, Gallagher TF,. A defect of steroid hormone metabolism in acute intermittent porphyria. Fed Proc. 1972; 31: 1293-7.
18. Marks GS, Stephens JK, Fischer PW, Morgan RO,. Hormonal effects on the regulation of hepatic heme biosynthesis. Mol Cell Biochem. 1979; 25: 111-23.
19. Nyberg S, Bäckström T, Zingmark E, Purdy RH, Poromaa IS,. Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome. Gynecol Endocrinol. 2007; 23: 257-66.
20. 4,5α-reductase activity in acute intermittent porphyria. J Exp Med. 1973; 138: 754-63.
21. Anderson KE, Bradlow HL, Sassa S, Kappas A,. Studies in porphyria. VIII. Relationship of the 5 alpha-reductive metabolism of steroid hormones to clinical expression of the genetic defect in acute intermittent porphyria. Am J Med. 1979; 66: 644-50.
22. Russell DW, Wilson JD,. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem. 1994; 63: 25-61.
23. Kondo KH, Kai MH, Setoguchi Y, Eggertsen G, Sjöblom P, Setoguchi T, et al,. Cloning and expression of cDNA of human Δ4-3-oxosteroid 5β-reductase and substrate specificity of the expressed enzyme. Eur J Biochem. 1994; 219: 357-63.
24. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, et al,. Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008; 99: 81-6.
25. Lenton EA, Landgren BM,. The normal menstrual cycle. In:, Shearman RP, (ed). Clinical reproductive endocrinology. Edinburgh: Churchill Livingstone, 1985. pp. 81-108.
26. Hammarbäck S, Bäckström T, Mac-Gibbon-Taylor B,. Diagnosis of premenstrual tension syndrome: description and evaluation of procedure for diagnosis and differential diagnosis. J Psychosom Obstet Gynaecol. 1989; 10: 25-42.
27. Sundström I, Andersson A, Nyberg S, Ashbrook D, Purdy RH, Bäckström T,. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology. 1998; 67: 126-38.
28. Timby E, Balgård M, Nyberg S, Spigset O, Andersson A, Porankiewicz-Asplund J, et al,. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl). 2006; 186: 414-24.
29. Purdy RH, Moore PH Jr, Rao PN, Hagino N, Yamaguchi T, Schmidt P, et al,. Radioimmunoassay of 3 alpha-hydroxy-5 alpha-pregnan-20-one in rat and human plasma. Steroids. 1990; 55: 290-6.
30. Kappas A, Bradlow HL, Gillette PN, Gallagher TF,. Studies in porphyria. I. A defect in the reductive transformation of natural steroid hormones in the hereditary liver disease, acute intermittent porphyria. J Exp Med. 1972; 136: 1043-53.
31. Haning RV Jr, Tantravahi U, Zhao Q, Hackett RJ, Canick JA,. 5α-Reductase 1 and 2 expression and activity in human ovarian follicles, stroma and corpus luteum as compared to neonatal foreskin. J Steroid Biochem Mol Biol. 1996; 59: 199-204.
32. Occhiato EG, Guarna A, Danza G, Serio M,. Selective non-steroidal inhibitors of 5α-reductase type 1. J Steroid Biochem Mol Biol. 2004; 88: 1-16.
33. Ottander U, Poromaa IS, Bjurulf E, Skytt A, Bäckström T, Olofsson JI,. Allopregnanolone and pregnanolone are produced by the human corpus luteum. Mol Cell Endocrinol. 2005; 239: 37-44.
34. Zhu YS, Imperato-McGinley JL,. 5α-Reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. 2009; 1155: 43-56.
35. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW,. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 1993; 92: 903-10.
36. Backstrom T, Andersson A, Baird DT, Selstam G,. The human corpus luteum secretes 5 alpha-pregnane-3,20-dione. Acta Endocrinol (Copenh). 1986; 111: 116-21.
37. Signorelli SS, Barresi V, Musso N, Anzaldi M, Croce E, Fiore V, et al,. Polymorphisms of steroid 5-α-reductase type I (SRD5A1) gene are associated to peripheral arterial disease. J Endocrinol Invest. 2008; 31: 1092-7.
38. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R,. Variants in the 5α-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab. 2006; 91: 4085-91.
39. Eminović I, Komel R, Prezelj J, Karamehić J, Gavrankapetanović F, Heljić B,. Gene analysis of steroid 5 α-reductase 1 in hyperandrogenic women. Croat Med J. 2005; 46: 664-9.
40. Hift RJ, Meissner PN,. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore). 2005; 84: 48-60.